WCA
CBAY

Windsor Creek Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Windsor Creek Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,770
Closed -$130K – 179
2021
Q2 		$130K Hold
29,770
– – 0.03% 164
2021
Q1 		$135K Hold
29,770
– – 0.04% 166
2020
Q4 		$171K Buy
+29,770
New +$225K 0.04% 178

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Windsor Creek Advisors's CBAY Position: Q3 2021 in Review

Windsor Creek Advisors sold out of Cymabay Therapeutics (CBAY) in Q3 2021, closing a stake of 29,770 shares — an estimated $130K sold.

Windsor Creek Advisors first reported a position in CBAY in Q4 2020 and held it in 3 quarters. The position peaked at $171K in Q4 2020. 113 funds tracked by Wall St. Rank hold CBAY as of Q3 2021.

  • Windsor Creek Advisors reported no remaining Cymabay Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Windsor Creek Advisors sold 29,770 Cymabay Therapeutics shares in Q3 2021, an estimated $130K.
  • Windsor Creek Advisors first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 3 quarters.
  • Windsor Creek Advisors's Cymabay Therapeutics position peaked at $171K in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2021.

Based on Windsor Creek Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.